Central Serous Chorioretinopathy Risk Factors in An Iranian Cohort: A Case-control Study

Overview

Journal J Ophthalmic Vis Res

Specialty Ophthalmology

Date 2024 Jan 22

PMID 38250227

Authors

Saeed Karimi

Nastaran Payandeh

Sahar Mahmoudi Nejad Azar

Hosein Nouri

Seyed-Hossein Abtahi

Affiliations

Soon will be listed here.

Abstract

Purpose: This study aimed to investigate the possible risk factors of central serous chorioretinopathy (CSCR) in an Iranian cohort.

Methods: We recruited 39 consecutive CSCR cases and 80 age-matched controls with no ocular pathology from the same medical center from March 2019 to March 2021. Enrolled patients underwent complete ophthalmological examination and extensive history taking in a referral setting. Logistic regression analysis was performed to detect any possible association of potential risk factors with CSCR.

Results: The mean age of CSCR patients was 40.697.71 years. The male-to-female ratio in cases and controls was 1:1.79 and 1.22:1, respectively. Logistic regression analysis revealed that alcohol consumption (odds ratio, OR: 62.0, 0.001), smoking (OR: 4.0, 95% CI: 1.47-10.85, 0.006), corticosteroid use (OR: 6.95, 95% CI: 2.64-18.28, 0.001), and high psychological stress (OR: 13.34, 95% CI: 4.68-38.02, 0.01) were significant risk factors for developing CSCR. Ischemic heart disease (=0.550), hypertension (=0.750), and hyperopia (=0.467) were not associated with the risk of CSCR. The most common form of steroid use was oral in both groups. No pregnant female was present in the study sample, precluding the assessment of its potential association with CSCR.

Conclusion: CSCR often affects individuals of productive working ages; thus, identifying its preventable risk factors is highly encouraged. Our results suggested that alcohol consumption, smoking, and high levels of psychological stress are independent, preventable risk factors for CSCR.

References

Carvalho-Recchia C, Yannuzzi L, Negrao S, Spaide R, Freund K, Rodriguez-Coleman H . Corticosteroids and central serous chorioretinopathy. Ophthalmology. 2002; 109(10):1834-7. DOI: 10.1016/s0161-6420(02)01117-x. View

Terao N, Koizumi H, Kojima K, Kusada N, Nagata K, Yamagishi T . Short axial length and hyperopic refractive error are risk factors of central serous chorioretinopathy. Br J Ophthalmol. 2019; 104(9):1260-1265. DOI: 10.1136/bjophthalmol-2019-315236. View

Nicholson B, Noble J, Forooghian F, Meyerle C . Central serous chorioretinopathy: update on pathophysiology and treatment. Surv Ophthalmol. 2013; 58(2):103-26. PMC: 3574296. DOI: 10.1016/j.survophthal.2012.07.004. View

Daruich A, Matet A, Dirani A, Bousquet E, Zhao M, Farman N . Central serous chorioretinopathy: Recent findings and new physiopathology hypothesis. Prog Retin Eye Res. 2015; 48:82-118. DOI: 10.1016/j.preteyeres.2015.05.003. View

Liu B, Deng T, Zhang J . RISK FACTORS FOR CENTRAL SEROUS CHORIORETINOPATHY: A Systematic Review and Meta-Analysis. Retina. 2015; 36(1):9-19. DOI: 10.1097/IAE.0000000000000837. View

Kaye R, Chandra S, Sheth J, Boon C, Sivaprasad S, Lotery A . Central serous chorioretinopathy: An update on risk factors, pathophysiology and imaging modalities. Prog Retin Eye Res. 2020; 79:100865. DOI: 10.1016/j.preteyeres.2020.100865. View

Chang Y, Weng S, Chang C, Wang J, Wang J, Jan R . Associations Between Topical Ophthalmic Corticosteroids and Central Serous Chorioretinopathy: A Taiwanese Population-Based Study. Invest Ophthalmol Vis Sci. 2015; 56(6):4083-9. DOI: 10.1167/iovs.14-16360. View

Chang Y, Weng S, Wang J, Jan R . Temporal Association between Topical Ophthalmic Corticosteroid and the Risk of Central Serous Chorioretinopathy. Int J Environ Res Public Health. 2020; 17(24). PMC: 7767174. DOI: 10.3390/ijerph17249455. View

Tsai D, Chen S, Huang C, Chou P, Chung C, Chan W . Risk of central serous chorioretinopathy in adults prescribed oral corticosteroids: a population-based study in Taiwan. Retina. 2014; 34(9):1867-74. DOI: 10.1097/IAE.0000000000000159. View

10.

Imamura Y, Fujiwara T, Spaide R . Frequency of glaucoma in central serous chorioretinopathy: a case-control study. Retina. 2009; 30(2):267-70. DOI: 10.1097/IAE.0b013e3181c2e0f4. View

11.

Yavas G, Kusbeci T, Kasikci M, Gunay E, Dogan M, Unlu M . Obstructive sleep apnea in patients with central serous chorioretinopathy. Curr Eye Res. 2013; 39(1):88-92. DOI: 10.3109/02713683.2013.824986. View

12.

Yannuzzi L . Type A behavior and central serous chorioretinopathy. Trans Am Ophthalmol Soc. 1986; 84:799-845. PMC: 1298752. View

13.

Chatziralli I, Kabanarou S, Parikakis E, Chatzirallis A, Xirou T, Mitropoulos P . Risk Factors for Central Serous Chorioretinopathy: Multivariate Approach in a Case-Control Study. Curr Eye Res. 2017; 42(7):1069-1073. DOI: 10.1080/02713683.2016.1276196. View

14.

Kumawat D, Ravi A, Sahay P, Alam T, Desai A, Kumar A . Systemic evaluation of patients with central serous chorioretinopathy: A case-control study. Eur J Ophthalmol. 2020; 31(6):3223-3230. DOI: 10.1177/1120672120975698. View

15.

Roshani M, Ahangar Davoodi N, Seyyedmajidi M, Zojaji H, Jahani Sherafat S, Hashemi M . Association of Helicobacter pylori with central serous chorioretinopathy in Iranian patients. Gastroenterol Hepatol Bed Bench. 2014; 7(1):63-7. PMC: 4017553. View

16.

Tittl M, Spaide R, Wong D, Pilotto E, Yannuzzi L, Fisher Y . Systemic findings associated with central serous chorioretinopathy. Am J Ophthalmol. 1999; 128(1):63-8. DOI: 10.1016/s0002-9394(99)00075-6. View

17.

Liew G, Quin G, Gillies M, Fraser-Bell S . Central serous chorioretinopathy: a review of epidemiology and pathophysiology. Clin Exp Ophthalmol. 2012; 41(2):201-14. DOI: 10.1111/j.1442-9071.2012.02848.x. View

18.

Chen S, Chen Y, Lian I . Increased risk of coronary heart disease in male patients with central serous chorioretinopathy: results of a population-based cohort study. Br J Ophthalmol. 2013; 98(1):110-4. DOI: 10.1136/bjophthalmol-2013-303945. View

19.

Haimovici R, Koh S, Gagnon D, Lehrfeld T, Wellik S . Risk factors for central serous chorioretinopathy: a case-control study. Ophthalmology. 2004; 111(2):244-9. DOI: 10.1016/j.ophtha.2003.09.024. View

20.

Toyama T, Ohtomo K, Noda Y, Ueta T . Polypoidal choroidal vasculopathy and history of central serous chorioretinopathy. Eye (Lond). 2014; 28(8):992-7. PMC: 4135256. DOI: 10.1038/eye.2014.132. View